Linperlisib
- Generic Name
- Linperlisib
- Drug Type
- Small Molecule
- Chemical Formula
- C28H37FN6O5S
- CAS Number
- 1702816-75-8
- Unique Ingredient Identifier
- 05HYK3CV9N
- Indication
用于既往接受过至少两种系统性治疗的复发或难治滤泡性淋巴瘤成人患者。
YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04500561
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT04379167
A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT04370405
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Phase 1
Completed
- Conditions
- Lymphoplasmacytic LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaDiffuse Large B Cell LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 43
- Registration Number
- NCT04279405
- Locations
- 🇨🇳
Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin, China
A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT04108325
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04049929
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
Phase 1
- Conditions
- B-cell Lymphoma RecurrentB-cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03757000
- Locations
- 🇨🇳
Peking Cancer Hospital, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath